The evolution of osteoporosis treatment
Almost half of women aged over 50 suffer from osteoporosis which is of significant public health concern. Its importance is set to rise further over time with an aging population. The prevention of fragile fractures avoids notable mortality and morbidity as well as saves noteworthy direct and indirect costs to the economy.
It has also been demonstrated that how our understanding of bone pathophysiology has given way to novel therapies in the form of combinations and altered durations of existing treatments, and also the newer drug therapies.
The database searching of PubMed and Embase was done to explore the randomized controlled trials of new therapies for osteoporosis. These searches were amplified with material presented in abstract form at international meetings. The new efficient drugs that appear encouraging in osteoporosis treatment encompasses the cathepsin K inhibitor, monoclonal antibodies against sclerostin and parathyroid hormone-related protein analog.
Although, some areas of disagreement other than the development of novel drug therapies is an issue of how best to use agents that are currently available to us; specially which agent to choose, alone or in combination; duration of therapy; how best to identify patients at highest risk of fracture, and to safeguard the highest possible adherence to medication. Many of these have been mentioned in other excellent review papers, and will not be examined in detail here. As with all new treatments, the outcomes are anticipated of long-term use and experience in ‘real life’ patient populations.
It can be concluded that the data is immediately required regarding the optimal duration of therapy; use of combination therapy; ordering of therapies for par excellence therapeutic effect. Also, as the stratified medicine becomes more strongly advised in all areas of therapy, its merits in osteoporosis as in other musculoskeletal conditions, is timely and valuable.